Acta Scientific Microbiology

Research ArticleVolume 1 Issue 6

Evaluating an Inactivated Infectious Bovine Rhinotracheitis Vaccine for Safety and Efficacy

Weiwei Su and Wei Wang*

Vaccine Development, Sinovet (Jiangsu) Biopharmaceutical Co. Ltd., Taizhou, Jiangsu, China

*Corresponding Author: Wei Wang, Vaccine Development, Sinovet (Jiangsu) Biopharmaceutical Co. Ltd., Taizhou, Jiangsu, China.

Received: April 03, 2018; Published: May 08, 2018

Citation: Weiwei Su and Wei Wang. “Evaluating an Inactivated Infectious Bovine Rhinotracheitis Vaccine for Safety and Efficacy”. Acta Scientific Microbiology 1.6 (2018).

Abstract

  An inactivated infectious bovine rhinotracheitis (IBR) vaccine was developed using BoHV-1 LN01, a field strain recently isolated from Northeast China. The vaccine was evaluated at three dose levels for safety and efficacy in fifteen healthy 6-to 7-month-old calves. Calves were vaccinated intramuscularly and boosted with a second intramuscular vaccination 21 days later. No site or systemic reactions were observed after the vaccination. Following homologous challenge, only one of fifteen vaccinated calves showed mild clinical signs, whereas all (5/5) non-vaccinated, challenged calves showed severe clinical signs. Neutralizing antibody titers against BoHV-1 were induced in vaccinated calves (GMTs 1:199 - 1:221) but not in unvaccinated controls (GMT < 1:2). BoHV-1 was recovered post challenge from two of the five calves (2/5) in each of the three vaccinated groups (Groups 1 - 3). However, virus was detected in all non-vaccinated control calves (5/5) and appeared earlier and persisted longer than in the vaccinated groups. Postmortem examination of vaccinated, challenged calves showed normal lungs and tracheas. All unvaccinated, challenged controls showed lung and tracheal lesions typical of IBR. Based on clinical signs and necropsy findings, protection rates were 100% in vaccinated Group 1 (5/5) and Group 2 (5/5), and 80% in vaccinated Group 3 (4/5). None of the unvaccinated animals was protected from challenge (0/5). These results demonstrate that the inactivated IBR vaccine provided effective protection against the wild type BoHV-1 challenge.

Keywords: Bovine Herpesvirus-1; Infectious Bovine Rhinotracheitis (IBR); Inactivated IBR Vaccine; Safety and Efficacy

Copyright: © 2018 Weiwei Su and Wei Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Member In






News and Events


  • Submission Timeline for Regular Issue
    Last date for submission of articles for regular Issues is October 30, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US